Targeting antioxidant defenses could overcome colorectal cancer drug resistance

A new review in Genes & Diseases highlights a potential vulnerability in colorectal cancer: the antioxidant defenses that help tumor cells survive treatment. The article examines how adjusting the activity of Nrf2, a regulator of these defenses, could help activate cell death pathways and address drug resistance.

Prepared by a team at China Medical University and affiliated hospitals, the review explores a balancing act. Nrf2 protects healthy intestinal cells from oxidative damage, yet persistent activation in cancer cells can strengthen their defenses and reduce sensitivity to chemotherapy. This dual role makes the pathway a promising but challenging therapeutic target.

At the center of this balance are reactive oxygen species, reactive molecules generated during cellular activity. Cancer cells operate under heightened oxidative stress and depend on protective systems to keep these molecules within tolerable limits. Disrupting that balance may push tumor cells toward death, although healthy tissues also require protection.

The review focuses on three interconnected processes: apoptosis, the controlled dismantling of cells; ferroptosis, an iron-dependent form of cell death driven by damage to membrane fats; and autophagy, the recycling machinery that can support survival or contribute to cell death depending on circumstances.

Nrf2 influences these processes by regulating antioxidant production, iron handling and cellular stress responses. In particular, it can suppress ferroptosis by reinforcing defenses against lipid damage. Inhibiting those defenses could make some colorectal cancer cells more vulnerable to treatments designed to trigger ferroptosis or increase oxidative stress.

However, the article emphasizes that switching Nrf2 off is not a universal solution. Under certain conditions, activating the pathway can also contribute to anticancer effects or protect normal intestinal tissue during treatment. Effective strategies therefore depend on the biological context, the medicine involved and the cells being targeted.

Potential approaches include combining Nrf2 modulators with chemotherapy, radiotherapy or agents that promote cell death pathways. Tumor-targeted delivery systems, including nanoparticles, may help concentrate treatment within cancer tissue while limiting effects elsewhere.

The review also highlights the importance of biomarkers, including Nrf2 pathway activity and related genetic features, to identify patients most likely to benefit. Interactions with immune cells and other supporting cells surrounding tumors add another layer of complexity.

Source:
Journal reference:

Yu, Y., et al. (2026) Rewiring redox defense: Nrf2-driven antioxidant signaling as a gateway to programmed cell death activation in colorectal cancer. Genes & Diseases. DOI: 10.1016/j.gendis.2026.102228. https://www.sciencedirect.com/science/article/pii/S235230422600200X?via%3Dihub

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Engineered bacteria carrying two anticancer components shrinks aggressive breast cancer in mice